Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 950 participants.

Also called NCT07684144

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 950 participants (planned count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07684144
  • EU CT 2025-524788-19-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada, Japan, Puerto Rico, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07684144. Randomized; double masking; primary purpose treatment. Start 2026-07-29 (actual); primary completion 2027-12-26 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
Condition
Obesity
Condition
Overweight
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Maridebart Cafraglutide
Intervention (Drug)
Placebo
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct07684144
Content hash
dcd70188a296bdd1c9352232ad1e635cf8836067f6562420766c7a85f95829ae